# Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genomics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.genomicsplc.com
- Total disclosed funding: $61M
- Latest round: Series B (Dec 6, 2018)
- Investors on record: 12

## About

Based in Oxford, the UK and founded in 2014 by CEO Professor Peter Donnelly, Professor Gil McVean, Dr. Gerton Lunter, and Dr. Chris Spencer, Genomics plc is a healthcare company that uses large-genetic information to develop precision healthcare tools and engage in drug discovery for individuals as well as for health systems. In 2018, Vertex Pharmaceuticals Inc., collaborated with Genomic plc for three years, extendable to five years, to use human genetics to improve the discovery of drugs for precision medicines. 
In 2020, Genomics plc incorporated its US subsidiary, Genomic Inc. In 2021, Genomics plc raised USD 30 million in venture funding co-led by returning investors F-Prime Capital and Foresite Capital, with participation from other returning investors. In 2021, Genomics plc launched a pilot study to predict patients’ risk of heart disease using an integrated polygenic and clinical risk tool. As of 2021, the company staffs over 100 employees across three offices in the UK and the US.  

The company’s algorithms and databases link minute variations across human genomes to changes in thousands of biological measurements and disease outcomes.  Genomics also delivers insights for healthcare systems, clinicians, and pharmaceutical companies. The company’s products are offered through its precision health division and therapeutics division. 

Genomics plc measures an individual’s genetic code and provides preventive solutions for genetic risks and other non-genetic factors including risk for cancers, cardiovascular diseases, autoimmune disorders, and diabetes.  The company provides a polygenic risk score as a summary of genetic predisposition to a particular health condition for over 30 diseases.  Genomics’s therapeutics division is engaged in the discovery and development of new medicines.


The company plans to utilize the proceeds from venture funding to develop a patient-centric, population health framework that enables a more proactive, and personalized approach to healthcare.

## Funding rounds

- Series B, Dec 6, 2018, $10M — Tanarra Capital, F-Prime Capital, Longview Innovation, Invesco Perpetual, Foresite Capital, Lansdowne Partners, Vertex Pharmaceuticals Incorporated, Woodford Patient Capital Trust, Oxford Sciences Enterprises
- Series B, Aug 28, 2018, $32M — Tanarra Capital, Longview Innovation, Invesco Perpetual, Lansdowne Partners, Vertex Pharmaceuticals Incorporated, Woodford Patient Capital Trust, Oxford Sciences Enterprises
- Series A, Nov 21, 2014, $16M — Longview Innovation, Invesco Perpetual, Lansdowne Partners, University of Oxford, Woodford Patient Capital Trust, Wylie Family Trust
- Seed, Mar 6, 2014, $1.7M — Longview Innovation, Oxford University Innovation Limited

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Seed, Series A, Series B
- Oxford University Innovation Limited — Seed
- Invesco Perpetual — Series A, Series B
- Lansdowne Partners (https://capitalatlas.ai/funds/lansdowne-partners) — Series A, Series B
- University of Oxford — Series A
- Woodford Patient Capital Trust — Series A, Series B
- Wylie Family Trust — Series A
- Tanarra Capital (https://capitalatlas.ai/funds/tanarra-capital) — Series B
- Vertex Pharmaceuticals Incorporated — Series B
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B